aTYR PHARMA (ATYR) Profit After Tax Growth (3y) (2017 - 2026)
aTYR PHARMA (ATYR) Profit After Tax Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.25% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.44% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -29.12% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 59.34% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 5.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.82% |
| Mar 31, 2026 | 3.32% |
| Dec 31, 2025 | -22.91% |
| Sep 30, 2025 | -24.80% |
| Jun 30, 2025 | -16.29% |
| Mar 31, 2025 | -6.98% |
| Dec 31, 2024 | -20.60% |
| Sep 30, 2024 | -31.01% |
| Jun 30, 2024 | -16.20% |
| Mar 31, 2024 | -29.36% |
| Dec 31, 2023 | -44.08% |
| Sep 30, 2023 | -19.78% |
| Jun 30, 2023 | -24.17% |
| Mar 31, 2023 | -106.63% |
| Dec 31, 2022 | -7.99% |
| Sep 30, 2022 | -32.88% |
| Jun 30, 2022 | -28.54% |
| Mar 31, 2022 | -25.58% |
| Dec 31, 2021 | -10.51% |
| Sep 30, 2021 | -2.57% |